



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Mundy *et al.*
Serial No. : 09/805,840
Filed : March 13, 2001
Title : METHODS OF TREATING MULTIPLE MYELOMA AND MYELOMA-
INDUCED BONE RESORPTION USING INTEGRIN ANTAGONISTS

Art Unit : 1644
Examiner : Maher M. Haddad

MAIL STOP RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Applicants submit a copy of Reference "AE". All of the other references were submitted to and/or cited by the Office in U.S. Serial No. 10/086,217, filed February 21, 2002, which is a continuation-in-part of the present application. Therefore, Applicants have not provided copies of these references, but will do so at the Examiner's request.

This statement is being filed with a Request for Continued Examination, and no fee is believed to be due. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney's Docket No. 10274-034001.

Respectfully submitted,

Date: 27 March 2006




Rolando Medina, Ph.D., J.D.
Reg. No. 54,756


Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

21294962.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

3/27/06
Date of Deposit

Signature
Terri L. Knox
Typed or Printed Name of Person Signing Certificate


 Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR 1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-034001	Application No. 09/805,840
	Applicant Mundy <i>et al.</i>		
	Filing Date March 13, 2001	Group Art Unit 1644	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,840,299	11/1998	Bendig			
	AB	6,632,927	10/2003	Adair et al.			
	AC	5,885,786	03/1999	Cabot, Myles			
	AD	6,692,742	2/17/2004	Nakamura			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AE	WO 97/49428	12/31/1997	WIPO			X (abst only)	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AF	Amit et al., "Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution," Science, 233(4765):747-753 (1986)
	AG	Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," Proc. Natl. Acad. Sci. USA, 79(6):1979-83 (Mar 1982)
	AH	Alexanian R. et al., "Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens." JAMA, 208(9):1680-5 (Jun 2, 1969)
	AI	Owens, R.J., Young, R.J., "The genetic engineering of monoclonal antibodies," J. Immunol. Methods, 168(2):149-165 (1994)
	AJ	Alsina, M. et al., "Development of an In Vivo Model of Human Multiple Myeloma Bone Disease," Blood, 87:1495-1501 (1996).
	AK	Attal, M. et al., "A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma," N. Engl. J. Med, 335:91-97 (1996)
	AL	Atkins C., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma," N. Engl. J. Med., 335:1844 (1996)
	AM	Oivanen, T. M. et al., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma," N. Engl. J. Med., 335:1844-1845 (1996)
	AN	Attal et al., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma – In Reply," N. Engl. J. Med., 335:1844-1845 (1996)
	AO	Bataille, R. et al., "Serum levels of Interleukin 6, a Potent Myeloma Cell Growth Factor, as a Reflect of Disease Severity in Plasma Cell Dyscrasias," J. Clin. Invest., 84:2008-2011 (1989).
	AP	Bataille, R. et al., "Mechanisms of Bone Lesions in Multiple Myeloma," Hematology/Oncology Clinics of North America, 6:285-295 (1992).
	AQ	Bataille, R. et al., "Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma," Blood, 86:685-691 (1995)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-034001	Application No. 09/805,840
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR 1.98(b))		Applicant Mundy <i>et al.</i>	
		Filing Date March 13, 2001	Group Art Unit 1644

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AR	Seymour, J. F., "Correspondence: Long-Term Pamidronate in Multiple Myeloma," J. Clin. Oncol., 16:2572 (1998)
	AS	Berenson, J. R., "Correspondence: Long-Term Pamidronate in Multiple Myeloma -- In Reply," J. Clin. Oncol., 16:2572-2573 (1998)
	AT	Boyce, B.F. et al., "Bolus Injections of Recombinant Human Interleukin-1 Cause Transient Hypocalcemia in Normal Mice," Endocrinology, 125:2780-2783 (1989).
	AU	Chauhan, D. et al., "Regulation of Interleukin 6 in Multiple Myeloma and Bone Marrow Stromal Cells," Stem Cells, 13 (suppl. 2):35-39 (1995)
	AV	Epstein J., "Myeloma Phenotype: Clues to Disease Origin and Manifestation," Hematology/Oncology Clinics of North America, 6:249-256 (1992).
	AW	Garrett, I. R. et al., "A Murine Model of Human Myeloma Bone Disease," Bone, 20:515-520 (1997).
	AX	Gossler, U. et al., "Predominant Role of $\alpha 4$ -integrins for distinct steps of lymphoma metastasis," Proc. Natl. Acad. Sci. USA, 93:4821-4826 (1996)
	AY	MacDonald, B. R. et al., "Effects of Human Recombinant CSF-GM and Highly Purified CSF-1 on the Formation of Multinucleated Cells with Osteoclast Characteristics in Long-Term Bone Marrow Cultures," J. Bone and Mineral Research, 1:227-233 (1986).
	AZ	Matsuura, N. et al., "Induction of Experimental Bone Metastasis in Mice by Transfection of Integrin $\alpha 4\beta 1$ into Tumor Cells," AM J. Pathol., 148:55-61 (1996).
	AAA	Mundy, G. R., "Myeloma Bone Disease," Euro J. Cancer, 34:246-251 (1998).
	ABB	Oyajobi, B. O. et al., "Expression of Rank Ligand (RankL) By Myeloma Cells Requires Binding to Bone Marrow Stromal Cells Via An $\alpha 4\beta 1$ -VCAM-1 Interaction," Second Joint Meeting of the American Society for Bone and Mineral Research and the International Bone and Mineral Society, San Francisco, California: Abstract 1133 (12/4/1998); Bone, 23(5 Supplement):p. S180 (1998)
	ACC	Papayannapoulou, T. and Nakamoto, B., "Peripheralization of hemopoietic progenitors in primates treated with anti-VLA ₄ integrin," Proc. Natl. Acad. Sci. USA 90:9374-9378 (1993).
	ADD	Qian, F. et al., "Expression of the Integrin $\alpha 4\beta 1$ on Melanoma Cells Can Inhibit the Invasive Stage of Metastasis Formation," Cell, 77:335-347 (1994).
	AEE	Vanderkerken, K. et al., "Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse," Brit. J. Cancer, 76:451-460 (1997).
	AFF	Roodman, G. D., "Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma", Database Medline 'Online!': US National Library of Medicine (NLM), Bethesda, MD, US, retrieved from STN, Database accession no. 1998026745, abstract.
	AGG	Akatsu et al., "Chinese Hamster Ovary Cells Expressing Alpha4beta1 Integrin Stimulate Osteoclast Formation in Vitro," Database BIOSIS 'Online!': Biosciences Information Service, Philadelphia, PA, US (August 1998) Database accession no. PREV199800429141, abstract.
	AHH	Michigami et al., "Interactions of Myeloma Cells with Bone Marrow Stromal Cells via Alpha4Beta1 Integrin - VCAM-1 is required for the Development of Osteolysis," Database SCISEARCH 'Online!', retrieved from STN, Database accession no. 684996.
	AII	Mori et al., "Anti- $\alpha 4$ Integrin Antibody Suppresses the Bone Disease of Myeloma and Disrupts Myeloma-marrow Stromal Cell Interactions," Journal of Bone and Mineral Research, 14 Supp. 1, p. S173, Abstract 1161 (1991).

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	